Industry's Off-Label Hearing Priorities Taking Shape
Executive Summary
Pfizer attorney raises impact on research and other key themes for the upcoming FDA public hearing.
You may also be interested in...
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.
Payers Want Access To US FDA's Pre-Submission Meetings
As sponsors push for more access to physicians, payers hope to be able to gather more pre-approval information about drugs – like they now can with devices – for budgeting and patient access.
‘Who Is The Arbiter?’ US FDA Asks As It Mulls Loosening Off-Label Reins
A drumbeat of court cases – and now a change in presidential administrations – signals that regulations on off-label communications need to change; but FDA still seems unsure how to relax its grip without letting go completely.